1697CHAPTER 221 Introduction to Parasitic Infections
and Trichuris infect about 1.5 billion individuals, and at least
30–100 million have strongyloidiasis. These infections are most common in resource-poor developing countries, especially where people
defecate outside and/or human feces is used as fertilizer (“night soil”).
Infection is transmitted either by ingestion of ova (A. lumbricoides,
T. trichiura, and E. vermicularis) or by active penetration of the skin by
larvae (hookworms and S. stercoralis) (Table S13-2).
Intestinal roundworms cause serious health problems in residents
of endemic regions with poor sanitation, but travelers are at low risk of
developing significant disease from most of these parasites. Intestinal
blockage and malnutrition from heavy Ascaris infections and anemia
from heavy hookworm infections are now restricted to areas of heavy
endemicity. Except in the case of Strongyloides and Capillaria, which
can reproduce in the body, multiple exposures over time are necessary for the development of severe disease. Strongyloides infection
persists over decades and can disseminate when the immune system is
compromised. Although Capillaria remains localized to the intestine,
infections can become so heavy that protein-losing enteropathy and
malnutrition cause serious disease.
The life cycles of Ascaris and the hookworms involve migration
through the heart and lungs before development into adults in the
intestine. In particular, Ascaris occasionally causes eosinophilic pneumonia (Loeffler’s syndrome) during heavy infections. Pinworms are
the most common causes of intestinal roundworm infection persisting
in the United States and other developed countries. The anal and perineal itching caused by pinworm migration out of the anus and subsequent egg deposition is well known to families throughout the world.
TISSUE ROUNDWORMS The major diseases caused by tissue roundworms are filariasis, angiostrongyliasis, gnathostomiasis, and trichinellosis. By far, the most important globally is filariasis; the thread-like
filarial worms infect an estimated 120 million individuals in tropical
and subtropical areas of the world. Four filarial species cause three
distinct diseases: lymphatic filariasis (Wuchereria bancrofti and Brugia
malayi), river blindness (Onchocercus volvulus), and loiasis (Loa loa,
the African eye worm). Humans, the major reservoir, acquire these
infections from bites of infected arthropods (Table S12-2). The larvae
develop into adults, which remain static in tissue: the lymphatics for
lymphatic filariasis and subcutaneous tissue for O. volvulus and L. loa.
After adults mate, next-stage larvae are produced, and their migration
causes additional damage.
Repeated bouts of migrating larvae and blocking of the lymphatics
by adults are necessary to establish the syndrome of lymphatic filariasis; thus, it is unusual for the short-term traveler (<3 months’ residence
in an endemic region) to develop significant disease. In river blindness,
the larvae produced by adult O. volvulus migrate through the skin and
eye, causing skin damage and eventual blindness. Loiasis is a milder
disease restricted to central and western Africa. Although both the
adults and the larvae of L. loa migrate through the skin and eye, many
infected individuals are asymptomatic, and the infection is often diagnosed only when an adult worm migrates across the subconjunctival
tissue and is visible to the patient and the physician. Red lumps in the
skin from heavy cutaneous migration are called Calabar swellings.
The other four major roundworm tissue infections are acquired by
ingestion of larvae in undercooked food. The sources for trichinellosis
are swine and other large mammals; for gnathostomiasis, freshwater
fish and chicken; for ancylostomiasis, snails, fish, prawns, and crabs;
and for Guinea worm, infected water fleas. Guinea worm infection
(dracunculiasis, caused by Dracunculus medinensis) has been almost
eradicated. Trichinella spiralis larvae penetrate the intestine and migrate
widely, with a preference for skeletal tissue; the release of eosinophils
and IgE causes muscle soreness and may cause palpebral swelling and
other manifestations of generalized allergic reactions. Angiostrongylus
cantonensis is the most common parasitic cause of eosinophilic meningitis. Ingested larvae penetrate the intestine and migrate to the brain
and meninges, where they quickly die and attract massive numbers
of eosinophils. Although complications can occur, most individuals
recover spontaneously. Gnathostoma spinigerum larvae also penetrate
the intestine and migrate, showing a preference for the skin, eyes, and
beef tapeworm, Taenia solium the pork tapeworm, and Diphyllobothrium latum the fish tapeworm. Hymenolepis nana is capable of completing its life cycle in the human intestine and is acquired by ingestion
of infected grain beetles or of ova from infected humans or mice. None
of these parasites causes significant damage, and infection is usually
asymptomatic. There are two occasional exceptions. When people
ingest T. solium ova from their own intestine or from another infected
individual, it can cause somatic infection. D. latum avidly absorbs
vitamin B12 in the intestine and can cause pernicious anemia in 1–2%
of infected Scandinavians with a genetic predisposition.
SOMATIC TAPEWORMS There are three major causes of somatic tapeworm infections. Two species of Echinococcus cause echinococcosis.
E. granulosus is acquired by accidental ingestion of ova from dogs
infected when fed the infected tissues of sheep or other animals by
sheepherders or hunters. E. multilocularis is transmitted primarily in
sub-Arctic areas when humans ingest ova from foxes, dogs, or cats
that have been infected through consumption of the tissues of infected
rodents. Both species cause hydatid cysts when the eggs hatch into larvae, penetrate the intestine, and migrate into the liver or lung. Ingested
T. solium ova cause somatic disease (cysticercosis) when the larvae
penetrate the intestine, migrate into tissue, and form cysts (cysterci),
usually in the muscles or central nervous system (CNS).
Trematodes Flukes also cause both intestinal and somatic infections (Chap. 234 and Table S12-1). Most fluke infections are localized
to Asia, Africa, Southeast Asia, or the Pacific islands. Infection with
intestinal flukes is usually asymptomatic, although heavy infections
sometimes cause abdominal discomfort and mucous diarrhea. Liver
flukes and lung flukes cause somatic infections when humans ingest
a larval form from an intermediate host. Adults develop in the intestine, migrate into adjacent tissues, and cause disease. The major liver
flukes (Clonorchis sinensis, Opisthorchis spp., and Fasciola hepatica)
are causes of recurrent bacterial cholangitis (due to obstruction) or
portal hypertension and cirrhosis. Only F. hepatica can be acquired
worldwide; it is especially common in sheep-raising areas, where
the animals ingest water plants (e.g., watercress). The lung flukes
(Paragonimus spp.) occur globally except in Europe; most lesions occur
as pulmonary cysts, although occasional lesions develop in the CNS or
the abdominal cavity.
The blood flukes cause schistosomiasis, one of the most common and
serious parasitic infections (Chap. 234 and Table S12-1). The major
species are Schistosoma mansoni, S. haematobium, and S. japonicum. All
are transmitted to humans when free-swimming larvae exit an infected
snail in freshwater and penetrate the skin. Swimmer’s itch sometimes
follows skin penetration but is usually of short duration. The larvae
then wander in the skin until they find a blood vessel and migrate to
the target organ. S. mansoni and S. japonicum migrate to the mesentery
vessels and eventually make their way to the liver, while S. haematobium targets the veins around the ureter and bladder. Extensive egg
deposition by S. mansoni and S. japonicum and the immune reactions
to the ova cause granuloma formation and, with many repeated exposures, portal vein obstruction and cirrhosis. The same process in the
ureters and bladders during infection with S. haematobium eventually
interferes with urine flow and leads to repeated urinary tract infections
and kidney damage.
■ ROUNDWORMS
Nematodes Roundworms are nonsegmented bisexual organisms.
The species that infect humans include intestinal and tissue groups.
Humans may also acquire certain nonhuman mammalian roundworms that either can be limited to the skin or can migrate to tissues
and cause serious disease (the larva migrans syndromes).
INTESTINAL ROUNDWORMS The major intestinal roundworms are
Ascaris lumbricoides, Necator americanus (New World hookworms),
Ancylostoma duodenale (Old World hookworms), Trichuris trichiura
(whipworms), Enterobius vermicularis (pinworms), and Strongyloides
stercoralis. Taken together, infections caused by intestinal roundworms
are the most common infections in the world. Ascaris, hookworms,
1698 PART 5 Infectious Diseases
meninges. Mechanical damage from the migration and inflammation
produced by the resultant immune reaction can cause boil-like lesions
on the skin, painful eye damage, and eosinophilic meningitis. Although
eosinophilic meningitis caused by G. spinigerum is less common than
that caused by A. cantonensis, it is often more severe and can result in
paralysis or brain hemorrhage.
PROTOZOAL INFECTIONS
■ INTESTINAL PROTOZOA
Entamoeba histolytica is the one intestinal protozoan that causes invasive disease. This disease consists of dysentery or bloody diarrhea that
must be differentiated from that due to bacteria such as Salmonella,
Campylobacter, and Shigella. Although amebiasis usually has a slower
onset with lower fever than these bacterial infections, E. histolytica can
disseminate from the bloodstream to cause distant abscesses, particularly of the liver. The diagnosis cannot be made by identification of the
characteristic cyst or trophozoites (Chap. 223) as they are identical to
those of the noninvasive E. dispar, which is more common globally.
Cryptosporidium and Giardia are the most common water-borne protozoal infections. Cryptosporidium can cause major outbreaks because it
is highly infectious and resistant to high levels of chlorine (Chap. 229).
Without immune reconstitution, immunosuppressed patients, particularly those with AIDS, can develop severe, even fatal watery diarrhea.
Infections caused by the remaining intestinal protozoans—Giardia, Isospora, Cyclospora, and microsporidia (Chap. 229)—have a much more
indolent course, with intermittent diarrhea. Microsporidia, unique
intracellular protozoa that form infectious spores, may cause limited
gastrointestinal infection in immunocompetent hosts, but patients
with AIDS can develop chronic diarrhea and wasting or disseminated
infection to the biliary or respiratory tract.
■ FREE-LIVING AMOEBAS
The free-living amoebas Acanthamoeba and Naegleria are found worldwide in freshwater and brackish water (Chap. 223 and Table S12-3).
Organisms of these two genera cause very different syndromes. In
immunocompromised individuals, Acanthamoeba may cause invasive
infection, with brain masses and skin lesions. However, all humans are
susceptible to Acanthamoeba keratitis after trauma to the eye and exposure to contaminated water. In contrast, naeglerial meningitis, acquired
in warm lakes or hot springs, causes sudden pyogenic and usually fatal
meningitis. Balamuthia, reported only from the Americas, causes indolent meningoencephalitis, with both cerebrospinal fluid pleocytosis
and a space-occupying lesion, in immunocompetent patients. Despite
the availability of miltefosine, which is active in vitro against Naegleria,
infection of the CNS is almost universally fatal.
■ BLOOD AND TISSUE PROTOZOANS
Plasmodium and Babesia Malaria, caused by six species of
Plasmodium, carries higher mortality rates than any other parasitic
infection (Chap. 224). All species are transmitted in tropical and subtropical areas by female Anopheles mosquitoes. Plasmodium falciparum
is most common in sub-Saharan Africa, where it causes more than
80% of malaria infections and 90% of malarial deaths. Infection with
P. falciparum may be particularly severe because the organism can
invade any erythrocyte, reaches very high parasite loads, damages
organs by adhering to vascular epithelium, and is the most likely
Plasmodium species to be resistant to antimalarial drugs. Plasmodium
vivax, the dominant cause of malaria outside sub-Saharan Africa,
reaches lower levels of parasitemia and exhibits less drug resistance because it invades only reticulocytes with Duffy antigen. Many
Africans, especially in the western part of the continent, lack the Duffy
blood group; consequently, Plasmodium ovale, another cause of milder
malaria, can compete successfully with P. vivax. Both P. vivax and P.
ovale produce persistent liver forms, which must be treated with primaquine (Chap. 222). Because malaria can cause a variety of symptoms
ranging from acute fever to coma, this diagnosis must be considered
in any traveler or immigrant from a malarial area. Babesia also infects
erythrocytes and may cause a nonspecific febrile illness or, in asplenic
patients, severe infection. This parasite is carried by ixodid ticks and
is geographically limited to the northeastern and midwestern United
States, with only sporadic cases in Europe and other temperate areas.
Trypanosomes The three species of trypanosomes all have flagellated bloodstream forms, but they cause very different diseases.
T. cruzi, the cause of Chagas disease, is transmitted in South and Central America in the feces of blood-sucking reduviid bugs (Chap. 227).
After initial parasitemia, patients are often asymptomatic for years
while the parasite multiplies intracellularly in muscle and ganglion
cells. Although only a minority of patients go on to develop organ damage (megaesophagus and cardiomyopathy), all infected patients can
spread the disease through transfusions, mother-to-child transmission,
and organ transplants.
African trypanosomiasis is limited to sub-Saharan Africa, where it is
transmitted by the bite of a tsetse fly. A history of a tsetse bite and the
presence of a painful chancre are strong diagnostic clues (Chap. 227).
Although the parasites causing this disease in western Africa (Trypanosoma brucei gambiense) and eastern Africa (T. brucei rhodesiense) look
identical, they are genetically and clinically distinct. T. b. gambiense
causes low-level parasitemia with cyclical fevers over months or years
before CNS invasion, whereas T. b. rhodesiense causes high-level parasitemia, invades the CNS early on, and can lead to death within weeks
of onset.
Leishmania Leishmaniasis is caused by more than 20 species of obligate intracellular protozoa transmitted by sandflies, which are present in
almost 100 countries in tropical and temperate zones (Chap. 226). A wide
spectrum of clinical symptoms result, ranging from self-healing, painless
skin ulcers to mucocutaneous disease with destruction of the nose and
palate to disseminated visceral leishmaniasis with hepatic and splenic
involvement. The resulting disease depends on the infecting strain and
the host immune response. Visceral leishmaniasis can present as an
acute febrile illness, with the later development of hepatosplenomegaly,
and is an AIDS-defining illness in HIV-infected patients. More than
90% of cases of visceral leishmaniasis occur in India, Bangladesh, Ethiopia, Sudan, and Brazil.
Toxoplasma Toxoplasma gondii is an obligate intracellular parasite
that is found worldwide. Infection follows ingestion of oocysts in food
or water contaminated by cat feces, ingestion of tissue cysts in undercooked meat, or transplacental transmission. After gastrointestinal
invasion, tachyzoites can invade any nucleated cell and cause lifelong
infection in most patients (Chap. 228). Clinical manifestations depend
on the host’s age and immune status at the time of infection. Congenital toxoplasmosis results from primary maternal infection; outcomes
are most severe early in pregnancy and include visual, hearing, and
cognitive impairments. Babies infected later in pregnancy may appear
normal but can develop chorioretinitis decades later. Primary infection
in immunocompetent hosts may be asymptomatic, may present as an
infectious mononucleosis–like syndrome or may manifest as chorioretinitis during outbreaks. During immunosuppression by AIDS or
organ transplantation, reactivation of latent cerebral infection can be
fatal unless diagnosed and treated early.
APPROACH TO THE PATIENT
Parasitic Infection
A thorough history and physical examination are the keys to diagnosis of any disease and particularly of parasitic infections. Because
many of the more serious parasitic infections are uncommon in the
United States, a travel history, particularly to developing nations,
is a critical component. The longer the stay in an area endemic for
significant parasitic infections, the greater the risk, even for healthy
travelers. In addition, other factors increase the chance of acquiring
these infections. Notably, immunocompromise greatly increases the
likelihood of developing some of the more serious parasitic infections. Even healthy travelers with adventure itineraries, extensive
travel to rural areas, or involvement in war zones or refugee camps
1699CHAPTER 221 Introduction to Parasitic Infections
TABLE 221-1 Parasitic Infections, by Organ System and Signs/Symptomsa
ORGAN SYSTEM, MAJOR
SIGN(S)/SYMPTOM(S) PARASITE(S) GEOGRAPHIC DISTRIBUTION COMMENTS
Skin
Serpentine rash Hookworm Worldwide Can cause anemia in heavy infections
Strongyloides Moist tropics and subtropics Disseminated infection in immunocompromise
Toxocara (animal roundworm) Tropical and temperate zones Cutaneous or visceral larva migrans
Itchy skin rash Onchocerca Mexico, Central/South America, Africa Larvae detectable in skin snips and nodules
Painless ulcers Leishmania Tropics and subtropics Amastigotes detectable in biopsies; may cause destructive
mucocutaneous infection; AIDS-defining infection
Skin nodules Onchocerca Mexico, South America, Africa Large nodules of adult worms
Loa loa (African eye worm) Western and central Africa Migratory nodules
Gnathostoma Southeast Asia and China Migratory nodules with eosinophilia
Painful nodules, especially
involving feet
Dracunculus (Guinea worm) Africa Nearly eradicated
Central Nervous System
Somnolence, seizures, coma Plasmodium falciparum Subtropics and tropics Cerebral malaria, especially in children
Trypanosoma brucei
rhodesiense
Sub-Saharan eastern Africa Painful chancre from tsetse fly bite; death in weeks to
months
Space-occupying lesions,
seizures
Acanthamoeba Worldwide Immunocompromised individuals
Balamuthia Americas Indolent meningoencephalitis with brain mass
Toxoplasma Worldwide Reactivation disease in immunocompromise; ringenhancing lesions; AIDS-defining infection
Taenia solium Mexico, Central/South America, Africa Cysticercosis; variable sized or calcified larval cysts on CT
Schistosoma japonicum Far East Aberrant eggs can form brain or spinal cord masses.
Schistosoma mansoni Africa, Central/South America Aberrant eggs can form brain or spinal cord masses.
Pyogenic meningitis Naegleria Worldwide Motile trophozoites in fresh cerebrospinal fluid; pyogenic;
rapid death
Eosinophilic meningitis Angiostrongylus (rat lung worm) Southeast Asia, Pacific, Caribbean Most common cause globally of eosinophilic meningitis;
spontaneous resolution
Gnathostoma Southeast Asia and China Migratory nodules
Eyes
Painful corneal ulcers Acanthamoeba Worldwide Freshwater and brackish water; corneal trauma; long-wear
contact lenses
Corneal opacification Onchocerca Mexico, Central/South America, Africa Immune response to microfilaria in cornea
Congenital or adult visual
loss
Toxoplasma Worldwide Primary infection in pregnancy and normal hosts;
reactivation infection in immunocompromised
Retinal mass Toxocara Worldwide Ocular larva migrans
Visible roundworm in eye Onchocerca Mexico, Central/South America, Africa Worms may cross eye during migration.
L. loa Western and central Africa Worms may cross eye during migration.
Pain, possible vision loss Gnathostoma Southeast Asia and China Migratory skin nodules, eosinophilia
Lungs
Pulmonary nodule/abscess Paragonimus Far East, Africa, Americas Ectopic migration to abdomen or central nervous system
Cough, transient infiltrates,
eosinophilia
Migrating helminths Worldwide Loeffler’s syndrome from migrating Ascaris, hookworm,
Strongyloides
Heart
Pulmonary edema P. falciparum (complication) Tropics and subtropics End-organ damage from severe malaria
Cardiomegaly, arrhythmias Trypanosoma cruzi Mexico, Central/South America Late amastigote infection of myocardium; AIDS-defining
infection
Gastrointestinal Tract
Hepatosplenomegaly Malaria (multiple episodes) Tropics and subtropics Splenomegaly with anemia and recurrent fever are
hallmarks of malaria.
S. mansoni Africa, Central/South America Portal obstruction with cirrhosis and late varices
Leishmania donovani complex Tropics and subtropics Visceral leishmaniasis; AIDS-defining infection
Hepatomegaly Entamoeba histolytica Tropics Acute with fever, right-upper-quadrant pain; or chronic with
enlarged liver; hypoechoic abscess(es) on ultrasound or CT
Echinococcus Sheep-raising areas Characteristic cysts of liver > lung
Fasciola Sheep-raising areas Eosinophilia
(Continued)
1700 PART 5 Infectious Diseases
TABLE 221-1 Parasitic Infections, by Organ System and Signs/Symptomsa
ORGAN SYSTEM, MAJOR
SIGN(S)/SYMPTOM(S) PARASITE(S) GEOGRAPHIC DISTRIBUTION COMMENTS
Cholangitis Clonorchis China, Southeast Asia Recurrent cholangitis and late cholangiocarcinoma
Microsporidia Worldwide AIDS
Cryptosporidium Worldwide AIDS-defining infection
Bloody diarrhea E. histolytica Tropics Less fever than in diarrhea of bacterial etiology
S. mansoni Africa, Central/South America Only in heavy, acute infection with fever and eosinophilia
S. japonicum Far East Only in heavy, acute infection
Watery diarrhea Cryptosporidium Worldwide Severe in immunocompromised patients
Giardia Worldwide Foul-smelling stool with steatorrhea
Isospora belli Worldwide Fever, abdominal pain, chronic diarrhea
Microsporidia Worldwide Chronic diarrhea with AIDS
Capillaria Southeast Asia, Egypt Malabsorption, wasting
Passage of large
roundworm (>6 cm)
Ascaris Worldwide Patients may confuse the roundworm with an earthworm.
Small roundworms visible
around anus
Pinworm Worldwide Anal itching; eggs rarely detected by ova and parasite
(O&P) exam
Trichuris Worldwide Rectal prolapse with heavy infection in children
Passage of tapeworm
segments
T. solium or Taenia saginata Worldwide Usual reason for seeking medical care
Diphyllobothrium latum Worldwide Pernicious anemia in genetically predisposed
Scandinavians
Genitourinary System
Itchy discharge Trichomonas vaginalis Worldwide Common sexually transmitted disease of both sexes
Hematuria Schistosoma haematobium Africa Hematuria with negative cultures, urinary tract infections,
and late bladder cancer
Muscular System
Myalgias, myositis Trichinella Worldwide Palpebral swelling; high-level eosinophilia
Bloodstream
Fever without localizing
symptoms
Plasmodium Tropics and subtropics Consider in any patient from a malarious area.
Babesia New England, United States Geographically limited; worse with splenectomy
T. brucei rhodesiense, T. brucei
gambiense
Sub-Saharan Africa Limited to tsetse fly range; painful chancre; adenopathy
and cyclical fevers; early (rhodesiense) or late (gambiense)
central nervous system involvement
Filariae Asia, India Periodic fever with eosinophilia, adenolymphangitis,
chronic lymphangitis
L. donovani complex Tropics and subtropics Hepatosplenomegaly, fever, wasting; AIDS-defining
infection
a
See also text and Tables S12-1, S12-2, and S12-3 for vectors and routes of transmission.
(Continued)
are at increased risk. Immigrants from developing countries may
seek care for symptoms or signs associated with parasitic infections.
Information on the patient’s immunization history and adherence to appropriate malarial chemoprophylaxis is critical. The
recent approval of the first parasitic vaccine against P. falciparum is
very exciting, but it will be targeted only for children in high prevalence areas because of its modest efficacy. For example, typhoid
fever is much less likely to be the cause of prolonged fever in an
immunized individual. Similarly, hepatitis A or B is unlikely to be
the cause of jaundice and fever in fully immunized patients. In this
era of increasing drug resistance, even adherence to appropriate
malarial chemoprophylaxis does not guarantee that fever is not
malarial. Nevertheless, most travelers who acquire malaria have
taken inadequate or no prophylaxis. Although these considerations
do not prove that the symptoms are caused by parasites, they narrow the differential diagnosis.
There are many other important aspects of the history, including
when symptoms began. Was the individual still in the endemic
area at the time, or did the symptoms commence after return to
the United States? If they started during travel, was any treatment
received? Malaria must be the first consideration in a febrile patient
returning from an endemic area. If the patient was well upon return
from travel, the timing of symptom onset is a critical point. For
example, if the chief manifestation is fever that began >10–14 days
after departure from the endemic region, many tropical diseases
can be ruled out, including dengue fever, chikungunya fever, and
Zika virus infection. On the other hand, fever beginning several
months or later after return makes malaria a likely diagnosis. Travelers’ diarrhea, the most common complaint of travelers, is usually
caused by bacteria or viruses and resolves in a short time with or
without treatment. Travelers’ diarrhea that persists for weeks is
much more likely to be parasitic in origin.
Most patients who consult physicians after international travel
either have troublesome symptoms or have been referred for symptoms or signs whose source was unclear to a referring caregiver.
After a careful travel history including the individual’s symptoms
and the exact geographic zones visited, a thorough physical examination must be conducted. The symptoms, signs, and physical
findings should help to establish possible diagnoses. Table 221-1
breaks down the symptoms of major parasitic infections by organ
system and geographic distribution, with comments on clinical and
epidemiologic associations.
1701CHAPTER 222 Agents Used to Treat Parasitic Infections
Parasitic infections continue to afflict more than half of the world’s
population and impose a substantial health burden, particularly in
underdeveloped nations, where they are most prevalent. The reach
of some parasitic diseases, including malaria, has expanded over the
past few decades as a result of factors such as deforestation, population
shifts, global warming, and other climatic events. Although there have
been significant advances in vaccine development and vector control,
chemotherapy remains the single most effective means of controlling
parasitic infections. Efforts to combat the spread of some diseases
are hindered by the development and spread of drug resistance, the
limited introduction of new antiparasitic agents, the proliferation of
counterfeit medications, and, most recently, profiteering, which has
dramatically increased the cost of once-affordable agents. However,
there are good reasons to be optimistic. Ambitious global initiatives
aimed at controlling or eliminating threats such as AIDS, tuberculosis, and malaria have demonstrated successes. The ongoing efforts of
multinational partnerships to address the substantial burden imposed
by neglected tropical diseases have generated mechanisms to develop
and deploy effective antiparasitic agents. In addition, the development
of vaccines against several tropical diseases continues.
This chapter deals exclusively with the agents used to treat infections due to parasites. Specific treatment recommendations for the
parasitic diseases of humans are listed in subsequent chapters. Many
of the agents discussed herein are approved by the U.S. Food and Drug
Administration (FDA) but are considered investigational for the treatment of certain infections. Drugs marked in the text with an asterisk (*
)
are available through the Centers for Disease Control and Prevention
(CDC) Drug Service (telephone: 404-639-3670; email: drugservice@
cdc.gov; www.cdc.gov/ncpdcid/dsr/). Drugs marked with a dagger (†)
are available only through their manufacturers; contact information for
these manufacturers may be available from the CDC.
Table 222-1 presents a brief overview of each agent (including some
drugs that are covered in other chapters), along with major toxicities,
spectrum of activity, and safety for use during pregnancy and lactation.
Albendazole Like all benzimidazoles, albendazole acts by selectively binding to free β-tubulin in nematodes, inhibiting the polymerization of tubulin and the microtubule-dependent uptake of glucose.
Irreversible damage occurs in gastrointestinal (GI) cells of the nematodes, resulting in starvation, death, and expulsion by the host. This
fundamental disruption of cellular metabolism offers treatment for a
wide range of parasitic diseases.
222 Agents Used to Treat
Parasitic Infections
Thomas A. Moore
Acknowledgment
The author gratefully acknowledges the substantial contributions of
Charles E. Davis, MD, to this chapter in the previous editions.
■ FURTHER READING
Ashley EA et al: Malaria. Lancet 391:1608, 2018.
Fink D et al: Fever in the returning traveler. BMJ 360:j5773, 2018.
Rupali P: Introduction to tropical medicine. Infect Dis Clin N Am
33:1, 2019.
Thwaites GE, Day NPJ: Approach to fever in the returning traveler.
N Engl J Med 376:6, 2017.
Vos T et al: Global, regional, and national incidence, prevalence and
years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systemic analysis for the Global Burden of Disease
Study 2016. Lancet 390:1211, 2017.
Albendazole is poorly absorbed from the GI tract, a feature that is
advantageous for the treatment of intestinal helminths but not for that
of tissue helminth infections (e.g., hydatid disease and neurocysticercosis), which requires that a sufficient amount of active drug reach the
site of infection. Administration with a high-fat meal (~40 g) increases
the drug’s absorption by up to five-fold. The metabolite albendazole
sulfoxide is responsible for the drug’s therapeutic effect outside the
gut lumen. Albendazole sulfoxide crosses the blood–brain barrier,
reaching a level significantly higher than that achieved in plasma. The
high concentrations of albendazole sulfoxide attained in cerebrospinal
fluid (CSF) may explain the efficacy of albendazole in the treatment of
neurocysticercosis.
Albendazole is extensively metabolized in the liver, but there are few
data regarding the drug’s use in patients with hepatic disease. Single-dose
albendazole therapy in humans is largely without side effects (overall
frequency, ≤1%). More prolonged courses (e.g., as administered for
cystic and alveolar echinococcal disease) have been associated with
liver function abnormalities and bone marrow toxicity. Thus, when
prolonged use is anticipated, the drug should be administered in
treatment cycles of 28 days interrupted by 14-day intervals off therapy.
Prolonged therapy with full-dose albendazole (800 mg/d) should be
approached cautiously in patients also receiving drugs with known
effects on the cytochrome P450 system.
Amodiaquine Amodiaquine has been widely used in the treatment of malaria for >60 years. Like chloroquine (the other major
4-aminoquinoline), amodiaquine is now of limited use because of the
spread of resistance. Amodiaquine interferes with hemozoin formation
through complexation with heme. It is rapidly absorbed and acts as a
prodrug after oral administration; the principal plasma metabolite,
monodesethylamodiaquine, is the predominant antimalarial agent.
Amodiaquine and its metabolites are all excreted in urine, but there
are no recommendations concerning dosage adjustment in patients
with impaired renal function. Agranulocytosis and hepatotoxicity can
develop with repeated use; therefore, this drug should not be used
for prophylaxis. Despite widespread resistance, amodiaquine is effective in some areas when combined with other antimalarial drugs
(e.g., artesunate, sulfadoxine-pyrimethamine), particularly in children.
Although on the World Health Organization’s List of Essential Medicines, amodiaquine is not yet available in the United States.
Amphotericin B See Table 222-1 and Chap. 211.
Antimonials* Despite associated adverse reactions and the need
for prolonged parenteral treatment, the pentavalent antimonial compounds (designated Sbv
) have remained the first-line therapy for
all forms of leishmaniasis throughout the world, primarily because
they are affordable and effective and have survived the test of time.
Pentavalent antimonials are active only after bioreduction to the trivalent Sb(III) form, which inhibits trypanothione reductase, a critical
enzyme involved in the oxidative stress management of Leishmania
species. The fact that Leishmania species use trypanothione rather
than glutathione (which is used by mammalian cells) may explain the
parasite-specific activity of antimonials. The drugs are taken up by the
reticuloendothelial system, and their activity against Leishmania species may be enhanced by this localization. Sodium stibogluconate is the
only pentavalent antimonial available in the United States; meglumine
antimoniate is used principally in francophone countries.
Resistance is a major problem in some areas. Although low-level
unresponsiveness to Sbv
was identified in India in the 1970s, incremental increases in both the recommended daily dosage (to 20 mg/kg) and
the duration of treatment (to 28 days) satisfactorily compensated for
the growing resistance until around 1990. There has since been steady
erosion in the capacity of Sbv
to induce long-term cure in patients with
kala-azar who live in eastern India. Co-infection with HIV impairs the
treatment response.
Sodium stibogluconate is available in aqueous solution and is
administered parenterally. Antimony appears to have two elimination
phases. When the drug is administered IV, the mean half-life of the first
phase is <2 h; the mean half-life of the terminal elimination phase is
1702 PART 5 Infectious Diseases
TABLE 222-1 Overview of Agents Used for the Treatment of Parasitic Infections
DRUGS BY CLASS PARASITIC INFECTION(S) ADVERSE EFFECTS
MAJOR DRUG–DRUG
INTERACTIONS
PREGNANCY
CLASSa
BREAST
MILK
4-Aminoquinolines
Amodiaquine Malariab Agranulocytosis, hepatotoxicity No information Not assigned Yesc
Chloroquine Malariab Occasional: pruritus, nausea,
vomiting, headache, hair
depigmentation, exfoliative dermatitis,
reversible corneal opacity
Rare: irreversible retinal injury, nail
discoloration, blood dyscrasias
Antacids and kaolin: reduced
absorption of chloroquine
Ampicillin: bioavailability reduced
by chloroquine
Cimetidine: increased serum
levels of chloroquine
Cyclosporine: serum levels
increased by chloroquine
Not assignedd Yesc
Piperaquine Malariab Occasional: GI disturbances None reported Not assigned Yes
8-Aminoquinolines
Primaquine Malariab Frequent: hemolysis in patients with
G6PD deficiency
Occasional: methemoglobinemia, GI
disturbances
Rare: CNS symptoms
Quinacrine: potentiated toxicity of
primaquine
Contraindicated Yes
Tafenoquine Malariab Frequent: hemolysis in patients with
G6PD deficiency, mild GI upset
Occasional: methemoglobinemia,
headache
No information Not assigned Yes
Aminoalcohols
Halofantrine Malariab Frequent: abdominal pain, diarrhea
Occasional: ECG disturbances
(dose-related prolongation of QTc
and PR interval), nausea, pruritus;
contraindicated in persons who have
cardiac disease or who have taken
mefloquine in the preceding 3 weeks
Concomitant use of agents
that prolong QTc interval
contraindicated
C No
information
Lumefantrine Malariab Occasional: nausea, vomiting,
diarrhea, abdominal pain, anorexia,
headache, dizziness
Plasma levels increased by
darunavir and nevirapine,
decreased by etravirine
Not assigned No
information
Aminoglycosides
Paromomycin Amebiasis,b
infection with
Dientamoeba fragilis,
giardiasis, cryptosporidiosis,
leishmaniasis
Frequent: GI disturbances (oral dosing
only)
Occasional: nephrotoxicity, ototoxicity,
vestibular toxicity (parenteral dosing
only)
No major interactions Oral: B
Parenteral: not
assignedd
No
information
Amphotericin B
Amphotericin B
deoxycholate
Amphotec (InterMune)
Amphotericin B
lipid complex, ABLC
(Abelcet)
Amphotericin B,
liposomal (AmBisome)
Leishmaniasis,e
amebic
meningoencephalitis
Frequent: fever, chills, hypokalemia,
hypomagnesemia, nephrotoxicity
Occasional: vomiting, dyspnea,
hypotension
Antineoplastic agents: renal
toxicity, bronchospasm,
hypotension
Glucocorticoids, ACTH, digitalis:
hypokalemia
Zidovudine: increased myelo- and
nephrotoxicity
B No
information
Antimonials
Pentavalent antimonyf
Meglumine antimoniate
Leishmaniasis Frequent: arthralgias/myalgias,
pancreatitis, ECG changes (QT
prolongation, T wave flattening or
inversion)
No major interactions
Antiarrhythmics and tricyclic
antidepressants: increased risk of
cardiotoxicity
Not assigned
Not assigned
Yes
No
information
Artemisinin and
derivatives
Malariag Occasional: neurotoxicity (ataxia,
convulsions), nausea, vomiting,
anorexia, contact dermatitis
Arteether No information Not assigned Yesc
Artemether Artemether levels decreased
by darunavir, etravirine, and
nevirapine
C Yesc
Artesunatef Mefloquine: levels decreased
and clearance accelerated by
artesunate
C Yesc
Dihydroartemisinin Mefloquine: increased absorption Not assigned Yesc
(Continued)
1703CHAPTER 222 Agents Used to Treat Parasitic Infections
TABLE 222-1 Overview of Agents Used for the Treatment of Parasitic Infections
DRUGS BY CLASS PARASITIC INFECTION(S) ADVERSE EFFECTS
MAJOR DRUG–DRUG
INTERACTIONS
PREGNANCY
CLASSa
BREAST
MILK
Atovaquone Malaria,b
babesiosis Frequent: nausea, vomiting
Occasional: abdominal pain,
headache
Plasma levels decreased by
rifampin, tetracycline, atazanavir,
efavirenz, lopinavir/ritonavir;
bioavailability decreased by
metoclopramide
C No
information
Azoles
Fluconazole
Itraconazole
Ketoconazole
Leishmaniasis Serious: hepatotoxicity
Rare: exfoliative skin disorders,
anaphylaxis
Warfarin, oral hypoglycemics,
phenytoin, cyclosporine,
theophylline, digoxin, dofetilide,
quinidine, carbamazepine,
rifabutin, busulfan, docetaxel,
vinca alkaloids, pimozide,
alprazolam, diazepam, midazolam,
triazolam, verapamil, atorvastatin,
cerivastatin, lovastatin,
simvastatin, tacrolimus,
sirolimus, indinavir, ritonavir,
saquinavir, alfentanil, buspirone,
methylprednisolone, trimetrexate:
plasma levels increased by azoles
Carbamazepine, phenobarbital,
phenytoin, isoniazid, rifabutin,
rifampin, antacids, H2
-receptor
antagonists, proton pump
inhibitors, nevirapine: decreased
plasma levels of azoles
Clarithromycin, erythromycin,
indinavir, ritonavir: increased
plasma levels of azoles
C Yes
Benzimidazoles
Albendazole Ascariasis, capillariasis,
clonorchiasis, cutaneous
larva migrans, cysticercosis,b
echinococcosis,b
enterobiasis, eosinophilic
enterocolitis, gnathostomiasis,
hookworm, lymphatic
filariasis, microsporidiosis,
strongyloidiasis, trichinellosis,
trichostrongyliasis,
trichuriasis, visceral larva
migrans
Occasional: nausea, vomiting,
abdominal pain, headache, reversible
alopecia, elevated aminotransferases
Rare: leukopenia, rash
Dexamethasone, praziquantel:
plasma level of albendazole
sulfoxide increased by ~50%
C Yesc
Mebendazole Ascariasis,b
capillariasis,
eosinophilic enterocolitis,
enterobiasis,b
hookworm,b
trichinellosis,
trichostrongyliasis,
trichuriasis,b
visceral larva
migrans
Occasional: diarrhea, abdominal pain,
elevated aminotransferases
Rare: agranulocytosis,
thrombocytopenia, alopecia
Cimetidine: inhibited mebendazole
metabolism
C No
information
Thiabendazole Strongyloidiasis,b
cutaneous
larva migrans,b
visceral larva
migransb
Frequent: anorexia, nausea, vomiting,
diarrhea, headache, dizziness,
asparagus-like urine odor
Occasional: drowsiness,
giddiness, crystalluria, elevated
aminotransferases, psychosis
Rare: hepatitis, seizures,
angioneurotic edema, StevensJohnson syndrome, tinnitus
Theophylline: serum levels
increased by thiabendazole
C No
information
Triclabendazole Fascioliasis, paragonimiasis Occasional: abdominal cramps,
diarrhea, biliary colic, transient
headache
No information Not assigned Yes
Benznidazole Chagas disease Frequent: rash, pruritus, nausea,
leukopenia, paresthesias
No major interactions Not assigned No
information
Clindamycin Babesiosis, malaria,
toxoplasmosis
Occasional: pseudomembranous
colitis, abdominal pain, diarrhea,
nausea/vomiting
Rare: pruritus, skin rashes
No major interactions B Yesc
Diloxanide furoate Amebiasis Frequent: flatulence
Occasional: nausea, vomiting,
diarrhea
Rare: pruritus
None reported Contraindicated No
information
(Continued)
(Continued)
No comments:
Post a Comment
اكتب تعليق حول الموضوع